Drug intelligence / Profile preview

alaproclate

Development stage: Discontinued
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

Alaproclate is a small molecule antidepressant that was developed in the 1970s by Astra AB (now AstraZeneca) as one of the first selective serotonin reuptake inhibitors (SSRIs). It acts primarily by inhibiting neuronal serotonin reuptake, thereby increasing serotonin levels in the synaptic cleft. In addition to its SSRI activity, alaproclate has been found to act as a non-competitive NMDA receptor antagonist, though it does not exhibit discriminative stimulus properties similar to phencyclidine. The drug was investigated for use in depression and dementia but development was discontinued due to concerns over hepatotoxicity observed in animal studies[1][3][6][7].

Other names: alaproclate hydrochloride

Targets

SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on alaproclate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alaproclate.

Explore the full profile